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Abstract
Background: Accumulated evidence has demonstrated that Mammalian hepatitis B X-interacting protein (HBXIP)
has broad roles in cancer. Although HBXIP is associated with a variety of cancers, the HBXIP protein expression level
and its clinical significance in ovarian cancer have not yet been determined. The aim of this study is to investigate
the association between HBXIP expression and the clinicopathological features of ovarian cancer patients to
determine whether HBXIP may be correlated with a poor prognosis in ovarian cancer patients.
Methods: HBXIP protein expression was assessed in a well-characterized series of ovarian cancer tissue samples
(n = 120) with long-term follow-up, using immunohistochemistry to determine the location pattern and
expression of HBXIP in ovarian cancer. The localization of HBXIP was detected in SKOV-3 ovarian cancer cells
using immunofluorescence (IF) staining. The relationship between high HBXIP expression and the clinicopathological
features of ovarian cancer patients was analyzed by Chi-square and Fisher’s exact test. Overall survival (OS) rates of all
the ovarian cancer patients were calculated using the Kaplan-Meier method, and univariate and multivariate analyses
were performed using the Cox proportional hazards regression model.
Results: IF staining revealed strongly positive signals for HBXIP in both cytoplasm and nucleus, but mainly in the
cytoplasm of SKOV-3 ovarian cancer cells. High HBXIP expression was predominantly observed in ovarian cancer
tissues but not the adjacent non-tumor ovarian tissues. The strongly positive rate of HBXIP expression was 60.0%
(72/120) in ovarian cancer and was significantly higher than in adjacent non-tumor tissues (17.4%, 4/23) (P = 0.
000). High HBXIP expression was positively correlated with the occurrence of lymph node metastases (P = 0.025),
histological grade (P = 0.036) and clinical stage (P = 0.003). The patients with high HBXIP expression had lower
overall survival (OS) rates. Moreover, multivariate analysis indicated that HBXIP, in addition to the clinical stage,
was a significant independent prognostic factor in patients with ovarian cancer.
Conclusions: High-level expression of HBXIP is associated with the progression of ovarian cancer and may be an
effective biomarker for poor prognostic evaluation as well as a potential molecular therapy target for ovarian
cancer patients.
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Background
Ovarian cancer is one of the common lethal malignan-
cies in women and the most common cause of gyneco-
logic cancer deaths [1]. Most patients are diagnosed in
advanced stages, so clinical treatment and prognosis are
not satisfactory. Currently, clinical characteristics in
ovarian cancer, such as the FIGO stage, tumor type, the
presence of peritoneal metastases, lymph node status,
and morphological characteristics, are the most import-
ant prognostic factors [2]. Therefore, early diagnosis and
early treatment are the most effective methods of pre-
vention and treatment of ovarian cancer, and efficient
screening methods can significantly reduce the mortality
rate of patients and improve the prognosis.
Mammalian hepatitis B X-interacting protein (HBXIP)
is a conserved 18 kDa protein, which was originally
identified due to its interaction with the C terminus of
the hepatitis B virus X protein [3]. HBXIP was shown to
interact with the hSuv3 protein, which encodes an NTP-
dependent DNA/RNA DEXH box helicase predomin-
antly localized in mitochondria [4]. Furthermore, HBXIP
also functions as a regulatory component in amino acid-
induced activation of mTORC1 in cell growth [5]. Much
evidence has demonstrated that hepatitis B virus X-
interacting protein plays broad roles in several types of
cancers, including breast cancer, ovarian cancer and he-
patocellular carcinoma. Previous studies reported that
HBXIP was able to promote breast cancer cell prolifera-
tion and migration via activation of transcription factors
[6–11]. It also promotes the migration of breast cancer
cells through modulating microtubule acetylation medi-
ated by GCN5 [12]. Similarly, the oncoprotein HBXIP
promotes the migration of ovarian cancer cells through
the upregulation of S-phase kinase-associated protein 2
by Sp1 [13]. In addition, HBXIP functions as a cofactor
for survivin and serves as a link between the cellular
apoptosis machinery and a viral pathogen involved in
hepatocellular carcinogenesis [14]. HBXIP increases
hepatoma HepG2 cell-induced endothelial cell migra-
tion, proliferation, and angiogenesis, and plays an im-
portant role in tumorigenesis by enhancing angiogenesis
in HCC [15]. Similarly, HBXIP can markedly enhance
angiogenesis and growth of breast cancer through upreg-
ulating the expression and secretion of FGF8 and VEGF
[16]. Therefore, the abnormal expression of HBXIP may
facilitate carcinogenesis and tumor progression.
Although HBXIP is associated with a variety of cancers,
the HBXIP protein expression level and its clinical signifi-
cance in ovarian cancer have not yet been determined.
The aim of this study is to investigate the association
between HBXIP expression and the clinicopathological
features of ovarian cancer patients to determine whether
HBXIP may be correlated with poor prognosis in ovarian
cancer patients. We used immunohistochemistry (IHC) to
identify HBXIP in ovarian cancer tissues and examined
the association of HBXIP protein expression with the
clinicopathological features of ovarian cancer. We also
assessed the prognostic value of high HBXIP expression
in patients with ovarian cancer.
Methods
Ethic statement
This research complied with the Helsinki Declaration and
was approved by the Human Ethics Committee and the
Research Ethics Committee of Yanbian University Medical
College. Patients were informed that the resected speci-
mens were stored by the hospital and potentially used for
scientific research and that their privacy would be main-
tained. Follow-up survival data were collected retro-
spectively through medical record analyses.
Clinical samples
A total of 143 human ovarian tissue samples were used for
this study, including 120 ovarian cancer tissues, and 23
adjacent non-tumor tissues. These tumors were selected
randomly from patients undergoing surgery between 2004
and 2009 and stored in the Tumor Tissue Bank of Yanbian
University Medical College. All tissues were routinely fixed
in 10% buffered formalin and embedded in paraffin blocks.
The study protocol was approved by the institutional
review board of Yanbian University Medical College. The
pathological parameters, including age, tumor size, occur-
rence of distant metastases, clinical stage, differentiation,
occurrence of nodal metastases and survival data, were
carefully reviewed in all 120 ovarian cancer cases.
All patients were female between the ages of 42 to
78 years. A total of 120 patients, 65 cases, were 55 years
old or over, and 55 cases were patients below 55 years of
age. All cases were confirmed by pathological examin-
ation. For the tumor sizes, 59 cases were less than or
equal to 5 cm, and 61 cases were greater than 5 cm.
TNM staging was assessed according to the staging sys-
tem established by the American Joint Committee on
Cancer (AJCC). Of the 120 ovarian cancer patients, 39
cases were stages I-II, while 81 cases were stages III-IV.
For the histological grade, 41 cases were defined as
grade-1, 28 cases were grade-2, and 51 cases were grade-
3. In addition, 43 cases had distant metastases and 77
cases had no distant metastases. Additionally, 60 cases
had lymph node (LN) metastases, and 60 cases had no
LN metastases. None of the patients received radio-
chemotherapy before surgery. The 120 ovarian cancer
patients had been followed for 10 years or until death.
The actual survival months of ovarian cancer patients
are presented in Additional file 1: Table S. In this study,
in 23 cases, adjacent non-tumor lung tissues were col-
lected from the cancer resection margin.
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Immunohistochemical (IHC) staining
HBXIP was purchased from the Dako ProteinTech
Group (#14492-1-AP, ProteinTech, USA) of the United
States of America. The following steps were performed
using the EnVision method. Briefly, 4 μm-thick tissue
sections were dewaxed in the standard manner, followed
by gradient ethanol hydration, antigen retrieval in hot
citrate buffer and washing in PBS buffer. Then, a 1:500
dilution of rabbit HBXIP antibody was added and the
sample was incubated overnight at 4 °C. The sample
was labeled with horseradish peroxidase anti mouse
secondary antibodies at room temperature for 45 min,
followed by DAB coloration, counterstaining, and neu-
tral gum sealing. PBS solution was used as the negative
control.
Evaluation of the IHC staining
Two pathologists (Lin Z & Che S) who did not possess
knowledge of the clinical data examined and scored all
tissue specimens. In case of discrepancies, a final score
was established by reassessment by both pathologists on
a double-headed microscope. Briefly, the IHC staining for
HBXIP was semi-quantitatively scored as ‘-’ (negative) (no
or less than 5% positive cells), ‘+’ (5–25% positive cells),
‘++’ (26–50% positive cells) and ‘+++’ (more than 50%
positive cells). A cytoplasmic/nuclear expression pat-
tern was considered positive staining. Tissue sections
scored as ‘++’ and ‘+++’ were considered strong posi-
tives (high-level of expression) for HBXIP. For survival
data analysis, ‘++’ or ‘+++’ scored samples were considered
as high HBXIP expression and ‘-’or ‘+’ scored samples
were considered as low HBXIP expression.
Immunofluorescence (IF) staining analysis
IF staining was used to detect the sub–cellular
localization of HBXIP in SKOV-3 ovarian cancer cells.
All steps were performed at RT. SKOV-3 cells were
grown on coverslips to 70–80% confluence, then fixed
with 4% paraformaldehyde for 10 min. After 24 h, cells
were permeabilized with 0.5% TritonX-100 for 10 min.
After blocking with 3% bovine albumin fraction V
(A8020, Solarbio, Beijing, China) for 1 h, the slides were
quickly and gently washed with PBS. The cells were then
incubated with the HBXIP antibody (1:1000) at 4 °C
overnight, followed by incubation with Alexa Fluor 488
goat anti-rabbit IgG (H + C) (A11008, 1:1000, Invitrogen,
USA) for 1 h. After washing with PBS, cells were coun-
terstained with 4’,6-diamidino-2-phenylindole (DAPI)
(C1006, Beyotime, Shanghai, China) and the coverslips
were mounted with Antifade Mounting Medium (P0126,
Beyotime, Shanghai, China). IF signals were visualized
and recorded with a BX53 Olympus microscope.
Statistical methods
All statistical analyses were performed by SPSS17.0 stat-
istical software (SPSS Inc., Chicago, IL, USA). Statisti-
cally significant associations between HBXIP expression
and clinicopathological parameters were determined by
Chi-square (χ2) or Fisher’s test. The survival rate was es-
timated using the Kaplan-Meier method, and differences
in survival curves were analyzed using the Log-rank
tests. Multivariate analysis was performed using the Cox
proportional hazards regression model on all significant
characteristics measured for univariate analysis. P < 0.05
was considered statistically significant.
Results
High expression of HBXIP protein in ovarian cancer
To determine the subcellular localization of HBXIP, IF
staining for HBXIP protein was performed in SKOV-3
ovarian cancer cells. IF staining revealed that strongly
positive signals for HBXIP were present in both cytoplasm
and nucleus, but mainly in the cytoplasm of SKOV-3 ovar-
ian cancer cells (Fig. 1). IHC staining demonstrated that
the expression of HBXIP was positive in 101 (84.2%) of
the 120 cancer patients and strongly positive in 72 (60.0%)
of the 120 patients (Table 1). Further analysis revealed that
HBXIP staining was predominantly observed in ovarian
cancer tissue but not the adjacent non-tumor ovarian
tissues/non-cancerous tissues (P < 0.01). As shown in
Fig. 2, HBXIP was detected in both cytoplasm and nucleus
Fig. 1 Immunofluorescence staining for HBXIP protein in SKOV-3 ovarian cancer cells. SKOV-3 ovarian cancer cells were immunostained for HBXIP
(red). Nuclei were visualized by DAPI staining (blue). HBXIP protein was localized in both cytoplasm and nucleus, but mainly in the cytoplasm of
SKOV-3 ovarian cancer cells
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but primarily in the cytoplasm of cancer cells, with a com-
bined pattern of staining predominating.
Correlation between HBXIP expression status and
clinicopathological features of ovarian cancer
To evaluate the relationship between HBXIP and ovarian
cancer progression, we analyzed the correlation between
high HBXIP expression and clinicopathological features
of ovarian cancer. As summarized in Table 2, overex-
pression of HBXIP was significantly correlated with lymph
node metastases, histological grade and the clinical stage.
However, there were no significant correlations between
the expression level of HBXIP and patient age, tumor size
or distant metastases in patients with ovarian cancer. For
the histological grade, the strongly positive expression of
HBXIP was significantly higher in Grade-3 ovarian
cancers (72.5%, 37/51) than in Grade-2 (57.1%, 16/28) and
Grade-1 (46.3%, 19/41) cancers. Similarly, overexpression
of HBXIP showed a correlation with the clinical stage of
ovarian cancer. The strongly positive expression rate of
HBXIP protein was 69.1% (56/81) in ovarian cancers with
an advanced clinical stage (stage III–IV), which was
significantly higher than in cases in the early clinical stage
(stage I–II) (41.0%, 16/39). Additionally, the strongly
positive expression rate of HBXIP was also higher in
ovarian cancer with lymph node metastases (70.0%, 42/60)
than in cases without metastases (50.0%, 30/60).
Taken as a whole, the expression of HBXIP was
Table 1 Expression of HBXIP protein in ovarian cancer
Diagnosis No. of case HBXIP Positive case rate (%) Strong positive case rate (%)
- + ++ +++
Ovarian cancer 120 19 29 37 35 84.2%** 60.0%**
Adjacent non-tumor ovarian 23 15 4 4 0 34.8% 17.4%
Positive rate: percentage of positive cases with +, ++, and +++ staining score
Strongly positive rate (high-level expression): percentage of positive cases with ++ and +++ staining score
**p < 0.01 compared with adjacent normal ovarian
Fig. 2 IHC staining of HBXIP protein in ovarian tumor samples. a HBXIP protein was negative in adjacent non-tumor ovarian tissues. b Diffuse and
strong positive HBXIP protein signal in mucinous adenocarcinoma. c HBXIP protein was showed diffuse and strong positive staining in serous car-
cinoma. d Diffuse and strong positive HBXIP protein signal in serous carcinoma. e Diffuse and strong positive HBXIP protein signal in the endome-
trioid adenocarcinoma. f HBXIP protein staining is negative in granulosa cell tumors. (Original magnification, 200× in a-f)
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positively correlated with lymph node metastases,
histological grade and clinical stage (Table 2).
High HBXIP expression is an independent biomarker of
poor prognosis in patients with ovarian cancer
To further substantiate the importance of high HBXIP
expression in ovarian cancer progression, we evaluated
the prognostic power of HBXIP in determining the OS
of 120 ovarian cancer patients using the Kaplan–Meier
method. Patients with high HBXIP expression exhibited
a lower rate of OS than those with low HBXIP expression
(Log-rank = 22.665, P = 0.000) (Fig. 3a). Moreover, survival
of patients with G1 (Log-rank = 4.345, P = 0.037), G2
(Log-rank = 5.038, P = 0.025) and G3 (Log-rank = 10.535,
P = 0.001) ovarian cancer was significantly lower in pa-
tients with tumors exhibiting high versus low HBXIP ex-
pression (Fig. 3b–d). Similarly, the patients with high
HBXIP expression had decreased OS compared to those
with low HBXIP expression in cases where LN metastases
were not present (−) (Log-rank = 8.979, P = 0.003) or in
cases when LN metastases were present (+) (Log-rank =
9.782, P = 0.002) (Fig. 3e–f ). Additionally, ovarian cancer
patients with high HBXIP expression had decreased OS
compared with those with low HBXIP expression in either
early-stage cases (Log-rank = 5.459, P = 0.019) or late-
stage cases (Log-rank = 9.595, P = 0.002) (Fig. 3g–h).
Univariate analysis demonstrated that the occurrence
of lymph node metastases (P = 0.029), histological grade
(P = 0.043), clinical stage (P = 0.005) and HBXIP expres-
sion status (P = 0.000) were all significantly associated
with OS in patients with ovarian cancer. These data
suggest that HBXIP may be a valuable prognostic
indicator in ovarian cancer. Multivariate analysis was
subsequently performed using the Cox proportional
hazards model for all significant variables examined in
the univariate analysis. We found that high expression
of HBXIP (P = 0.002) and clinical stage (P = 0.038) were
significant independent prognostic factors for survival
in ovarian cancer (Table 3).
Discussion
Mammalian HBXIP is a conserved ~18 kDa protein of
unclear function, which was originally identified because
of its interaction with HBx, and it is located at human
chromosome 1p13.3 [3]. HBXIP sequences are well con-
served among mammalian species, with close orthologs
found in all vertebrate species where sequence data ex-
ists thus far. Overexpression of HBXIP suppresses hepa-
titis B virus replication in HepG2 cells, in addition to
suppressing the transactivation phenotype of HBx [3].
Recent evidence has shown that viral HBx dysregulates
the function of cellular HBXIP, causing excessive centro-
some production and multipolar mitotic spindles that lead
to chromosome segregation defects, thereby creating
genetic instability, which is a hallmark of malignancy [17].
Increasing evidence indicates that HBXIP is associated
with the regulation of cell proliferation [18]. Moreover,
high HBXIP expression has been observed in some can-
cers. Wang F et al.’s findings indicate that one of the
functions of HBXIP involves proliferation regulation in
cancer cell lines and in the normal liver cell line, which
is related to cell-cycle transition through checkpoint
controls at the G0/G1 or G2/M phases and the down-
regulation of p27 [18]. Li H et al. also found that highly
expressed HBXIP accelerates the MDM2-mediated
degradation of p53 in breast cancer through modulating
the feedback loop of MDM2/p53, resulting in the fast
growth of breast cancer cells [19]. Li Y et al. have re-
ported that HBXIP promotes the migration of breast
cancer cells through increasing filopodia formation
involving MEKK2/ERK1/2/Capn4 signaling [20]. Xu F et
al. found that HBXIP promoted the proliferation of breast
cancer cells, resulting in the increase of S-phase cells,
through upregulating Skp2 via activating transcription fac-
tor E2F1 [6]. Importantly, they also reported that HBXIP
was able to stimulate the activity of the Skp2 promoter via
transcription factor Sp1 thus promoting the migration of
ovarian cancer cells [13].
Accumulating evidence demonstrates that glucose me-
tabolism reprogramming and abnormal lipid metabolism
Table 2 Relationship between HBXIP protein overexpression
and the clinicopathological features of ovarian cancer




≥ 55 65 36 (55.4%) 1.259 0.262
< 55 55 36 (65.5%)
Tumor size
≤ 5 cm 59 37 (62.7%) 0.356 0.551
> 5 cm 61 35 (57.4%)
M classification
M0 77 46 (59.7%) 0.006 0.938
M1 43 26 (60.5%)
Lymph node status
N0 60 30 (50.0%) 5.000 0.025*
N+ 60 42 (70.0%)
Histological grade
Grade-1 41 19 (46.3%) 6.629 0.036*
Grade-2 28 16 (57.1%)
Grade-3 51 37 (72.5%)
Clinical stage
I + II 39 16 (41.0%) 8.667 0.003**
III + IV 81 56 (69.1%)
*p < 0.05 and **p < 0.01
Wang et al. Journal of Ovarian Research  (2017) 10:26 Page 5 of 8
Fig. 3 Kaplan-Meier survival curves illustrating the significance of HBXIP expression in ovarian cancer. a OS rates of patients with high (n = 72)
and low (n = 48) HBXIP expression. b–d High HBXIP expression was strongly associated with poor OS in G1 (n = 19), G2 (n = 16) and G3 (n = 37).
e–f High HBXIP expression was strongly associated with poor OS in patients without lymph node metastasis (n = 30) and with lymph node metastasis
(n = 42). g–h High HBXIP expression was strongly associated with poor OS in early-stage (n = 16) and late-stage (n = 56). (a: Log-rank =22.665,
P = 0.000; b: Log-rank =4.345, P = 0.037; c: Log-rank = 5.038, P = 0.025; d: Log-rank = 10.535, P = 0.001; e: Log-rank =8.979, P = 0.003; f: Log-rank =
9.782, P = 0.002; g: Log-rank = 5.459, P = 0.019; h: Log-rank = 9.595, P = 0.002.)
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are hallmarks of tumorigenesis. In breast cancer,
HBXIP can enhance glucose metabolism reprogram-
ming through suppressing SCO2 and PDHA1. It also
contributes to abnormal lipid metabolism through
LXRs/SREBP-1c/FAS signaling [21, 22]. These findings
indicate that HBXIP can be used as a co-activator of
transcription factors to upregulate many genes in the
development of cancer. However, the molecular mecha-
nism of HBXIP-mediated promotion of tumor prolifer-
ation is still unclear; so far, no association of HBXIP
expression with the clinicopathological factors in ovarian
cancer patients has been reported.
In this study, we incorporated staining intensity and
percentage of positive tumor cells for the scoring of
HBXIP expression. Our reported results are similar to
the trends reported in the literature. Xu’s data showed
that the positive expression rate of HBXIP was 75%
(60/80) in clinical ovarian cancer tissue samples [13].
Similar to Xu’s studies, our study also indicated that
HBXIP staining was predominantly present in ovarian
cancer tissue but not the adjacent normal ovarian
tissues/non-cancerous tissues [13]. However, they did
not analysis the relationship between HBXIP expression
and clinicopathological features. In our study, we found
that staining of HBXIP was localized in both cytoplasm
and nucleus but mainly in the cytoplasm, and these ob-
servations were consistent with our IF staining results
in SKOV-3 ovarian cancer cells. Moreover, HBXIP ex-
pression was found to be related to the histological
grade and clinical stage in the 120 ovarian cancer pa-
tients. Here, we also found that the patients with high
HBXIP expression had lower OS than those with low
HBXIP expression, as determined using the Kaplan-
Meier method. Moreover, the Cox regression analysis
showed that HBXIP was an independent prognostic fac-
tor for OS, along with tumor clinical stage.
These statistics indicated that HBXIP is an important
biomarker for the detection of ovarian cancer. It is well
known that ovarian cancer is the most lethal malignant
tumor in gynecology. The diagnosis usually occurs in
the late stage, with a 5-years survival rate of less than
30% [23]. The incidence of ovarian cancer is increasing
year by year, and a large amount of data verify that there
is a clear relationship between the prognosis of ovarian
cancer and early detection. Early diagnosis of ovarian
cancer is the primary measure that needs to be taken to
reduce the mortality rate; therefore, in the field of gyne-
cologic oncology, the screening of ovarian cancer is of
great interest. In this study, we postulate that HBXIP
may be used as a tumor marker, combined with clinical
symptoms and signs, to detect high-risk groups and to
improve the early clinical diagnosis of ovarian cancer,
which may be have distinct value.
Conclusion
To summarize, our study provides evidence that high
HBXIP expression is correlated with the development of
ovarian cancer. This is the first study evaluating the rela-
tionship between HBXIP expression and clinicopathological
features of ovarian cancer patients, and it is of great signifi-
cance to screening and targeted therapy of ovarian cancer.
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